Results 71 to 80 of about 5,617 (179)

A State of the Art Review on the Recalcitrant Candidiasis as a Clue of Inborn Errors of Immunity in Newborns

open access: yesJournal of Immunology Research, Volume 2026, Issue 1, 2026.
Background Defects in the development or function of the immune system are characteristic of inborn errors of immunity (IEI), a diverse group of inherited disorders. IEI can manifest in various ways during the neonatal stage, posing a challenge in their identification and treatment. The family who have a background of IEI, including a previous instance
Mahsa Fattahi   +5 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, Volume 66, Issue S2, Page 121-143, December 2025.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Good's Syndrome Presenting With Weaning Failure From Ventilation and Myasthenia Gravis in a Post‐Thymectomy Patient

open access: yesRespirology Case Reports, Volume 13, Issue 11, November 2025.
This case highlights the importance of long‐term vigilance in patients with thymoma, even after apparently successful resection, as Good's syndrome may manifest years later. Clinicians should maintain a high index of suspicion for Good's syndrome in any thymectomized patient presenting with unexplained infections, diarrhoea, or autoimmune complications,
Asmita Anilkumar Mehta   +4 more
wiley   +1 more source

CVID Enteropathy Associated With Chronic Norovirus Infection: Background, Clinical Features, and Therapeutic Aspects

open access: yesReviews in Medical Virology, Volume 35, Issue 6, November 2025.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency, characterised by impaired antibody production, immune dysregulation, and a broad spectrum of clinical manifestations. Gastrointestinal involvement is frequent, affecting up to 20% of patients and significantly contributing to morbidity and ...
Györgyi Műzes, Ferenc Sipos
wiley   +1 more source

Campylobacter jejuni bacteremia and Helicobacter pylori in a patient with X-linked agammaglobulinemia [PDF]

open access: yes, 2010
We describe a 15-year-old patient with X-linked agammaglobulinemia who developed malabsorption and bacteremia due to infection of Helicobacter pylori and Campylobacter jejuni.
Claas, E.C.J.   +13 more
core   +1 more source

X-Linked Agammaglobulinemia Presenting with Secondary Hemophagocytic Syndrome: A Case Report

open access: yesCase Reports in Medicine, 2013
Introduction. Coincidence of X-linked agammaglobulinemia (XLA) and secondary hemophagocytic syndrome (sHS) is atypical. Both diseases are rare and pathogenesis of the latter one is not clearly known. Case Presentation. A 5-year-old boy was diagnosed both
Can Ozturk   +3 more
doaj   +1 more source

Optimizing Lentiviral Vector Production: Insights Into PiggyBac Transposase and Concatemeric Array Strategies

open access: yesBiotechnology Journal, Volume 20, Issue 10, October 2025.
Graphical Abstract and Lay Summary Transposase‐mediated integration provides a robust alternative for generating stable lentiviral vector producer cell lines. While yielding slightly lower maximum titers than concatemeric‐array methods, it requires less DNA, accelerates recovery, and delivers more consistent performance, supporting scalable LVV ...
Jona Röscheise   +7 more
wiley   +1 more source

Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?

open access: yesThe Turkish Journal of Pediatrics, 2019
The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA) as well as ...
Şükrü Çekiç   +4 more
doaj   +1 more source

Immune System‐Related Genetic Risk Factors for Inhibitory Antibody Development in Patients With Hemophilia: Reviewing an Old Problem From a New Perspective—A Narrative Review

open access: yesHealth Science Reports, Volume 8, Issue 10, October 2025.
ABSTRACT Background and Aims Hemophilia A and B are two of the most common bleeding disorders. Genetic risk factors are associated with the development of autoantibodies released in hemophilia patients against alternative factors and are the most important problems associated with the care of these patients. Objective In this study, we reviewed genetic
Fatemeh Zeylabi   +2 more
wiley   +1 more source

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

open access: yesVIEW, Volume 6, Issue 5, October 2025.
The recent advancements in the application of CRISPR/Cas9‐edited tumor‐associated immune cells in cancer therapy are summarized, including T lymphoid cells, natural killer cells, macrophages, and B lymphoid cells et al., exhibiting a potential impact on the pathological status of cancer. This review also addresses the current challenges associated with
Yuhui Ma   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy